This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax
by Zacks Equity Research
Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.
Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes
by Zacks Equity Research
Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
by Zacks Equity Research
Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.
Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -11.11% and 156.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Geron (GERN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Geron (GERN) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have performed compared to their sector so far this year.
J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023
by Zacks Equity Research
J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.
Karuna (KRTX) Stock Skyrockets 98.7% in a Month: Here's Why
by Zacks Equity Research
Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well
by Zacks Equity Research
Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.
Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat
by Zacks Equity Research
Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.
Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data
by Zacks Equity Research
Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.
All You Need to Know About Geron (GERN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
VERU's Shares Jump on Successful COVID-19 Study Results
by Zacks Equity Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
by Zacks Equity Research
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
by Zacks Equity Research
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints
by Zacks Equity Research
Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.
Novartis (NVS) Announces Positive Data on Oncology Drug
by Zacks Equity Research
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
by Zacks Equity Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
by Zacks Equity Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
by Zacks Equity Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Radius (RDUS) to Go Private With $890M Deal, Shares Gain
by Zacks Equity Research
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.